University of Miami: Sylvester Comprehensive Cancer Center
Miami, Florida 33146
23 studies enrolling now · 172 studies all time
What they study most
Abdominal Neoplasm, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute-graft-versus-host Disease, Adult Solid Tumor, Adult T-Cell Leukemia/Lymphoma (ATLL), Adult T-cell Leukemia-Lymphoma, Advanced Cancer, Advanced Gastrointestinal Stromal Tumors, Advanced Malignant Neoplasm, Advanced Non-squamous Non-small-cell Lung Cancer
Studies at this site
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer — Recruiting now
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer — Recruiting now
- A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies — Recruiting now
- Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant — Recruiting now
- CD4CAR for CD4+ Leukemia and Lymphoma — Recruiting now
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors — Recruiting now
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer — Recruiting now
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer — Recruiting now
- A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies — Recruiting now
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) — Recruiting now
- Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease — Recruiting now
- Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study — Recruiting now
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) — Recruiting now
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma — Recruiting now
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — Recruiting now
- A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) — Recruiting now
- First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma — Recruiting now
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors — Recruiting now
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma — Running, not enrolling
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study — Enrolling by invitation
- Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma — Completed
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) — Stopped early
- Expanded Access to Gallium Maltolate (GaM) — Available (expanded access)
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — Running, not enrolling
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) — Running, not enrolling
- Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study — Running, not enrolling
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) — Running, not enrolling
- Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies — Running, not enrolling
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Running, not enrolling
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer — Running, not enrolling
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS — Running, not enrolling
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma — Completed
- Avatrombopag vs. Placebo for CIT in GI Malignancies — Running, not enrolling
- A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin — Completed
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Running, not enrolling
- Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma — Available (expanded access)
- Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma — Completed
- Safety and Efficacy of APG-157 in Head and Neck Cancer — Running, not enrolling
- MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC — Completed
- Evolutionary Therapy for Rhabdomyosarcoma — Running, not enrolling
- A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors — Running, not enrolling
- A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors — Running, not enrolling
- A Trial of Vigil for Participants With Ovarian Cancer — Running, not enrolling
- GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Stopped early
- Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies — Completed
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling